Table 2 Clinical characteristics of the AID patients enrolled in the study when receiving MSC infusion
Disease | Variable | n (%) | |
|---|---|---|---|
SLE | Disease course | ≤ 12 m | 27 (6.7%) |
12–60 m | 75 (18.6%) | ||
> 60 m | 76 (18.8%) | ||
Treatment course | ≤ 12 m | 52 (12.9%) | |
12–60 m | 77 (19.1%) | ||
> 60 | 49 (12.1%) | ||
Dose of steroids | ≤ 10 mg | 66 (16.3%) | |
10–30 mg | 102 (25.2%) | ||
> 30 mg | 10 (2.5%) | ||
Types of immunosuppressants | 0 | 32 (7.9%) | |
1 | 56 (13.9%) | ||
≥ 2 | 90 (22.3%) | ||
SS | Disease course | ≤ 12 m | 7 (1.7%) |
12–60 m | 39 (9.7%) | ||
> 60 m | 26 (6.4%) | ||
Treatment course | ≤ 12 m | 24 (5.9%) | |
12–60 m | 40 (9.9%) | ||
> 60 | 8 (2.0%) | ||
Dose of steroids | ≤ 10 mg | 51 (12.6%) | |
10–30 mg | 20 (5.0%) | ||
> 30 mg | 1 (0.2%) | ||
Types of immunosuppressants | 0 | 19 (4.7%) | |
1 | 37 (9.2%) | ||
≥ 2 | 16 (4.0%) | ||
SSc | Disease course | ≤ 12 m | 8 (2.0%) |
12–60 m | 19 (4.7%) | ||
> 60 m | 12 (3.0%) | ||
Treatment course | ≤ 12 m | 15 (3.7%) | |
12–60 m | 19 (4.7%) | ||
> 60 m | 5 (1.2%) | ||
Dose of steroids | ≤ 10 mg | 26 (6.4%) | |
> 10 mg | 13 (3.2%) | ||
Types of immunosuppressants | 0 | 3 (0.7%) | |
1 | 23 (5.7%) | ||
≥ 2 | 13 (3.2%) | ||
RA | Disease course | ≤ 12 m | 3 (0.7%) |
12-60Â m | 7 (1.7%) | ||
> 60 m | 22 (5.4%) | ||
Treatment course | ≤ 12 m | 10 (2.5%) | |
12–60 m | 18 (4.5%) | ||
> 60 | 4 (1.0%) | ||
Dose of steroids | ≤ 5 mg | 15 (3.7%) | |
5–10 mg | 14 (3.5%) | ||
> 10 mg | 3 (0.7%) | ||
Types of immunosuppressants | 0 | 6 (1.5%) | |
1 | 14 (3.5%) | ||
≥ 2 | 12 (3.0%) | ||
PM/DM | Disease course | ≤ 12 m | 10 (2.5%) |
12–60 m | 13 (3.2%) | ||
> 60 m | 7 (1.7%) | ||
Treatment course | ≤ 12 m | 13 (3.2%) | |
12–60 m | 11 (2.7%) | ||
> 60 | 6 (1.5%) | ||
Dose of steroids | ≤ 5 mg | 11 (2.7%) | |
5–30 mg | 14 (3.5%) | ||
> 30 mg | 5 (1.2%) | ||
Types of immunosuppressants | 0 | 2 (0.5%) | |
1 | 14 (3.5%) | ||
≥ 2 | 14 (3.5%) | ||